Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare Conference
24 February 2023 - 10:00PM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the
Company) today announced that Peter Greenleaf, President and Chief
Executive Officer, will give a corporate presentation at the
upcoming investor healthcare conference.
- Oppenheimer 33rd Annual Virtual Healthcare Conference being
held March 13 – 15, 2023. Presentation time Tuesday, March 14, from
9:20 – 9:50 AM ET.
To participate in the audio webcast, interested parties can
access the live webcast under "News/Events” through the “Investors”
section of the Aurinia corporate website at
www.auriniapharma.com.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical
company focused on delivering therapies to treat targeted patient
populations that are impacted by autoimmune, kidney and rare
diseases with a high unmet medical need. In January 2021, the
Company introduced LUPKYNIS® (voclosporin), the first FDA-approved
oral therapy for the treatment of adult patients with active lupus
nephritis (LN). The Company’s head office is in Victoria, British
Columbia, its U.S. commercial hub is in Rockville, Maryland, and
the Company focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230224005026/en/
Investor/Media Contact: Aurinia@westwicke.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2023 to Apr 2024